FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
15 hours ago · Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue.
FDA Approves Injectable Opdivo for Many Types of Cancer
5 days ago · “This approval of subcutaneous nivolumab gives our patients a new option that can deliver consistent efficacy and comparable safety expected from IV nivolumab and offers a patient-centric treatment experience,” Saby George, MD, of Roswell Park Comprehensive Cancer Center, said in a news release. “Opdivo Qvantig offers faster ...
FDA Approves Subcutaneous Immunotherapy Opdivo Qvantig
1 day ago · News. The FDA has approved a new way to receive a cancer treatment called nivolumab (Opdivo). This new version, called Opdivo Qvantig, can be given as an injection under the skin instead of through an IV. ... George S, Bourion MT, Chacon MR, et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously ...
Halozyme Announces FDA Approval of Bristol Myers Squibb's …
Dec 30, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and ...
FDA Approves First Subcutaneous Nivolumab Injection in Most …
5 days ago · Additionally, a key powered secondary end point showed an overall response rate (ORR) of 24% (95% CI, 19-30) in the nivolumab and hyaluronidase-nvhy arm, compared with 18% (95% CI, 14-24) in the ...
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab …
Dec 27, 2024 · OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
Halozyme Announces FDA Approval of Bristol Myers Squibb's …
Dec 30, 2024 · News; PR Newswire; Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab ...
FDA Approves Subcutaneous Nivolumab in All Solid Tumor …
Dec 27, 2024 · The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) as a treatment for patients in all solid tumor indications for which nivolumab has already received approval, according to a press release from the FDA. 1
Nivolumab and AVD the New Standard in Hodgkin Lymphoma
Nov 14, 2024 · In the nearly 1,000-patient trial, treatment with nivolumab and a three-drug chemotherapy regimen called AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD combined with the targeted therapy brentuximab (Adcetris).
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid …
5 days ago · FRIDAY, Jan. 3, 2025 -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications. Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase.